Literature DB >> 2719731

Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma.

M B Kinsella1, E A Smith, K S Miller, E C LeRoy, R M Silver.   

Abstract

Interstitial pulmonary fibrosis is a common manifestation of systemic sclerosis (SSc) and is a pathologic feature shared by a variety of other diseases. In these other disease processes, the glycoprotein fibronectin (FN) has been shown to be released by the alveolar macrophage, and is thus implicated in the development of fibrosis. We therefore studied the release of FN by alveolar macrophages obtained by bronchoalveolar lavage of 17 patients with SSc and 14 controls. We found that SSc alveolar macrophages released significantly more FN than did those of controls. Furthermore, the level of FN correlated positively with the level of inflammation determined by cellular analysis of lavage fluid and negatively with carbon monoxide diffusing capacity. FN may therefore play a role in the development of lung fibrosis in SSc and may be a marker of alveolitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719731     DOI: 10.1002/anr.1780320511

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

Review 1.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

2.  Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren's syndrome.

Authors:  B Gudbjörnsson; R Hällgren; O Nettelbladt; R Gustafsson; A Mattsson; E af Geijerstam; T H Tötterman
Journal:  Ann Rheum Dis       Date:  1994-09       Impact factor: 19.103

3.  Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts.

Authors:  Yoshihiro Mimura; Hironobu Ihn; Masatoshi Jinnin; Yoshihide Asano; Kenichi Yamane; Kunihiko Tamaki
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

Review 4.  Biomarkers of scleroderma lung disease: recent progress.

Authors:  Faye N Hant; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 5.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

6.  Imaging of pulmonary disease in scleroderma with J001X scintigraphy.

Authors:  P Diot; E Diot; E Lemarie; J L Guilmot; J L Baulieu; E Asquier; C Valat; A Delarue; A Le Pape
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

7.  Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma.

Authors:  B Eckes; C Mauch; G Hüppe; T Krieg
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

8.  Bushen Yijing Decoction (BSYJ) exerts an anti-systemic sclerosis effect via regulating MicroRNA-26a /FLI1 axis.

Authors:  Zixuan Cheng; Jialin Zhang; Wanying Deng; Shaojian Lin; Donghai Li; Ke Zhu; Qing Qi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.